Skin cancer survival rates vary substantially by cancer type, stage at diagnosis, and treatment modality, with excellent prognosis for early-detected basal cell and squamous cell carcinomas (95-99% 5-year survival) but substantially poorer outcomes for advanced melanoma (25-40% 5-year survival for stage IIIC-IV). Overall U.S. melanoma survival has improved substantially over past two decades due to earlier detection (increased screening), improved treatment options (targeted therapy, immunotherapy), and refined staging allowing more precise prognostication. Understanding survival statistics, prognostic factors, and treatment outcomes enables informed patient counseling and realistic expectation-setting.

Melanoma Survival by Stage

Stage I-II (Localized Disease): Five-year survival rates exceed 90% for stage I melanoma (localized to skin only). Stage IA (Breslow <0.8 mm, no ulceration) shows 97% 5-year survival; stage IB (Breslow 0.8-1 mm or any thickness with ulceration) shows 92% survival. Stage IIA (Breslow 1-2 mm) shows 81% survival; stage IIB (Breslow 2-4 mm) shows 70% survival; stage IIC (Breslow >4 mm) shows 53% survival. Breslow thickness (primary tumor depth) is single strongest prognostic factor; thicker tumors carry substantially worse outcomes.

Stage III (Regional Node Involvement): Stage IIIA (1 positive node, micrometastases) shows 78% 5-year survival; stage IIIB (1-3 nodes, macroscopic disease or satellite lesions) shows 59% survival; stage IIIC (4+ nodes or in-transit metastases) shows 40% survival. Number of involved lymph nodes, size of nodal disease, and extent of in-transit disease strongly predict outcomes.

Stage IV (Distant Metastatic Disease): Five-year survival is 7-15% for stage IV disease with median overall survival 6-12 months historically. However, immunotherapy and targeted therapy have substantially improved outcomes in recent years; 2-year survival rates now reach 35-50% in series using checkpoint inhibitors, particularly for non-brain metastases.

Non-Melanoma Skin Cancer Survival

Basal Cell Carcinoma: Five-year survival exceeds 99% even for advanced BCC; disease-specific mortality is <0.5%. Recurrence risk varies with size, location, and histologic subtype: nodular BCC shows 5% recurrence; infiltrative/morpheaform BCC shows 10-20% recurrence. Metastatic BCC is exceedingly rare; mortality is usually from locally advanced disease causing morbidity rather than true death from metastatic spread.

Squamous Cell Carcinoma: Five-year survival for localized SCC is 95-98%. Regional lymph node involvement substantially worsens prognosis: stage IIIA (1 node) shows 75% 5-year survival; stage IIIB (multiple nodes) shows 50% survival. Distant metastases (stage IV) show <25% 5-year survival. SCC metastatic risk is 5-10% for primary tumors; risk increases substantially with high-risk features (>4 cm diameter, poor differentiation, perineural invasion).

Prognostic Factors Predicting Outcomes

Melanoma: Breslow thickness (tumor depth), ulceration status, mitotic rate, and Clark level are primary stage-determining prognostic factors. Sentinel lymph node status is powerful prognostic indicator: positive SLN confers stage IIIA status and substantially worsens prognosis compared to SLN-negative melanoma. Emerging prognostic markers include: (1) circulating tumor DNA burden (correlates with metastatic risk); (2) tumor-infiltrating lymphocyte density (high density predicts better outcomes); (3) mutation burden (high mutation burden may predict immunotherapy response); and (4) BRAF/NRAS mutation status (influences targeted therapy eligibility).

SCC: Histologic grade (well-, moderately-, poorly-differentiated), tumor size (>4 cm increases risk), depth of invasion, perineural invasion, and lymphovascular invasion predict aggressive behavior. Poorly-differentiated SCC shows metastatic risk approaching 15-20%; well-differentiated SCC shows <5% risk. Immunosuppression substantially worsens prognosis; transplant recipients with SCC show higher mortality and recurrence rates.

Treatment Impact on Survival

Immunotherapy: Anti-PD-1 antibodies (nivolumab, pembrolizumab) and anti-CTLA-4 antibodies (ipilimumab) substantially improve survival in advanced melanoma. Checkpoint inhibitor monotherapy achieves 2-year overall survival of 40-50% for stage IV melanoma compared to 10-15% historically. Combination immunotherapy (PD-1 + CTLA-4 inhibition) achieves superior response rates (~60%) but with increased toxicity.

Targeted Therapy: BRAF inhibitors (vemurafenib, dabrafenib) combined with MEK inhibitors (trametinib) benefit BRAF-mutant melanomas, achieving response rates 60-75% and median OS 12-18 months compared to 8-9 months with chemotherapy.

Adjuvant Therapy: For stage III melanoma, adjuvant checkpoint inhibitors reduce recurrence risk by 50% and improve 2-year overall survival by 15-20% compared to observation alone. Adjuvant targeted therapy in BRAF-mutant stage III melanoma also improves outcomes.

FAQ

Q: What is my survival rate if I have melanoma?
A: Highly dependent on stage. Stage I: >90% 5-year survival. Stage II: 70-90%. Stage III: 40-78%. Stage IV: 7-50% depending on treatment.

Q: Has survival improved over time?
A: Yes, substantially. Immunotherapy and targeted therapy have dramatically improved stage IV survival (historically 5-7% to current 35-50% 2-year survival). Earlier detection also improves overall survival.

Q: Does thickness of my melanoma matter?
A: Yes. Breslow thickness is the strongest prognostic factor. Thicker melanomas (>4 mm) have substantially worse prognosis (~50% 5-year survival) than thin melanomas (<1 mm, ~97% survival).

Q: Is basal cell carcinoma curable?
A: Yes. Mortality from BCC is extremely rare (<0.5%); standard treatments (surgery, radiation, topical therapy) achieve cure rates >95%.

References

  1. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3622-3632.
  2. Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004;54(3):131-149.
  3. Garbe C, Peris K, Ascierto PA, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline. Eur J Cancer. 2020;126:159-177.
  4. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer 8th edition staging system. CA Cancer J Clin. 2017;67(6):472-492.
  5. Bichakjian CK, Olencki T, Aasi SZ, et al. Merkel cell carcinoma, version 2.2015. J Natl Compr Canc Netw. 2015;13(12):1510-1516.
  6. Coit DG, Thompson JA, Algazi A, et al. Cutaneous melanoma, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(4):367-402.
  7. Kaufman HL, Kirkwood JM, Hodi FS, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013;10(10):588-598.
  8. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535-1546.
  9. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355.
  10. Weber JS, Atkins MB, Dronca RS, et al. KEYNOTE-001 investigators. BRAF-mutant melanoma brain metastases: activity of vemurafenib and cobimetinib. Pigment Cell Melanoma Res. 2016;29(3):340-347.